Type 2 Diabetes
Evidence reinforces efficacy, tolerability of Galvus as once-daily oral option in Type 2 Diabetes
Published in Obesity and Diabetes Week, January 1st, 2007
Pooled analyses from a number of Phase III studies showed significant improvements in blood sugar control among patients in this age group when treated with Galvus without the increased risk of side effects that often limits more aggressive treatment in these patients.
The efficacy of once-daily dosing for Galvus monotherapy was also highlighted...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity Research
Mindless eating leads us to eat 28-45% more calories when foods are low-fat - Pediatric Obesity
Obesity is cited as the number one kids' health issue - Obesity and Diabetes
New findings from Hospital for Sick Children in the area of obesity and diabetes described - Obesity and Diabetes
New obesity and diabetes research from State University of New York outlined - Obesity and Diabetes
New obesity and diabetes study findings have been published by scientists at Steno Diabetes Center - Obesity and Diabetes
Researchers from Erciyes University provide details of new studies and findings in the area of obesity and diabetes in adolescents - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
